COL 179

Drug Profile

COL 179

Alternative Names: COL-179

Latest Information Update: 11 Feb 2011

Price : $50

At a glance

  • Originator Onset Therapeutics
  • Developer Onset Dermatologics
  • Class Anti-inflammatories; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Clinical Phase Unknown Skin disorders

Most Recent Events

  • 11 Jun 2010 Clinical trials in Skin disorders in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top